Related Experiment Video
Updated: May 4, 2026
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
Large-scale structure-based virtual screening identifies diverse KNa1.1 (KCNT1) potassium channel inhibitors
Emily A Caseley1, Katie J Simmons2, Bethan A Cole1
1School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK.
Insights
Researchers identified novel KCNT1 inhibitors to treat drug-resistant childhood epilepsy. These compounds target KNa1.1 channel overactivity, offering potential new therapeutic avenues for this rare genetic disorder.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Severe drug-resistant childhood epilepsy is linked to KCNT1 gain-of-function variants.
- These variants increase KNa1.1 channel activity, leading to severe neurological symptoms.
- Current treatments offer limited relief and are often poorly tolerated.
Purpose of the Study:
- To accelerate the development of KCNT1 inhibitors.
- To identify molecules that bind to KCNT1 and suppress channel overactivity.
- To find potential starting points for new epilepsy drug development.
Main Methods:
- Large-scale virtual screening of compounds.
- Fluorescent thallium flux assays.
- Patch clamp electrophysiology.
Main Results:
- Identified eight structurally diverse, novel inhibitors of the KNa1.1 channel.
- Inhibitors demonstrated potency in the low micromolar range.
- Compounds showed potential for suppressing KCNT1 channel overactivity.
Conclusions:
- Novel KCNT1 inhibitors were identified through virtual screening and experimental validation.
- These compounds represent promising leads for developing effective treatments for KCNT1-associated epilepsy.
- Further development could lead to improved therapeutic options for patients with limited treatment benefits.
Abstract:
Severe drug-resistant childhood epilepsy is caused by KCNT1 gain-of-function genetic variants, resulting in increased KNa1.1 channel activity. KCNT1-associated epilepsy is thought to affect around 1 in 300,000 births worldwide. Current treatment for KCNT1 epilepsy only provides mild symptomatic relief and uses a cocktail of experimental medications which must be personalised for the individual and are often poorly tolerated. Critically, with many patients, no therapeutic benefit is achieved. We sought to address this by using large-scale virtual screening to accelerate the development of a molecule which binds directly to KCNT1 to supress overactivity. We purchased a total of 71 compounds and using a combination of fluorescent thallium flux assays and patch clamp electrophysiology, identified a series of eight structurally diverse, novel inhibitors of the KNa1.1 channel with potency in the low micromolar range. These provide potential starting points for further development of drugs to treat KCNT1-associated epilepsy.
Related Concept Videos
01:18Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
01:26Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:24Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....